Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.58 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.58 |
| ▸ | WNT3A | P56704 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1577340 | 1.00 | DDB1 (0.58) | DDB1CRBNWNT3ANAMPTGPR119 | |
| SCHEMBL23554870 | 0.93 | PDE4B (0.52) | DDB1CRBNWNT3ANAMPTGPR119 | |
| SCHEMBL30006758 | 0.93 | PDE4B (0.52) | DDB1CRBNWNT3ANAMPTGPR119 | |
| SCHEMBL1577006 | 0.91 | DDB1 (0.56) | DDB1CRBNWNT3ANAMPTGPR119 | |
| SCHEMBL1577433 | 0.89 | DDB1 (0.57) | DDB1CRBNWNT3ANAMPTGPR119 | |
| SCHEMBL17825347 | 0.88 | DDB1 (0.56) | DDB1CRBNWNT3ANAMPTGPR119 | |
| SCHEMBL14141962 | 0.85 | DDB1 (0.53) | DDB1CRBNWNT3ANAMPTGPR119 | |
| SCHEMBL1577715 | 0.85 | GPR119 (0.52) | DDB1CRBNWNT3ANAMPTGPR119 | |
| SCHEMBL1577678 | 0.84 | DDB1 (0.52) | DDB1CRBNWNT3ANAMPTGPR119 | |
| SCHEMBL666124 | 0.83 | DDB1 (0.60) | DDB1CRBNWNT3ANAMPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-4079734-B1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMR BIOTECHNOLOGY CO LTD (CN) | 2025-09-17 | — | — | EP | disclosed |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-4079734-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | ABCG2, CYP4F8, CYP3A5 | DDB1 4666/4885CRBN 3248/4885WNT3A 859/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | DDB1 4446/4885CRBN 815/4885WNT3A 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.